Cho, Sang Kyu
Manzoor, Beenish S. http://orcid.org/0000-0002-0329-3465
Sail, Kavita R.
Parisé, Hélène
Ravelo, Arliene
Shapouri, Sheila
Kapustyan, Tatyana
Sharmokh, Simon
Virabhak, Suchin
Davids, Matthew S.
Johnson, Scott
Funding for this research was provided by:
AbbVie
Genentech
Article History
First Online: 8 May 2020
Compliance with Ethical Standards
:
: Study conduct, design and financial support were provided by AbbVie Inc. and Genentech. Genentech is a member of the Roche group. AbbVie Inc., Genentech, and Medicus Economics, LLC participated in the design of the research, the analysis and interpretation of findings, and the manuscript writing, review, and approval. All authors contributed to the development of the manuscript and maintained control over the final content.
: Beenish Manzoor, Kavita Sail, Simon Sharmokh, and Tatyana Kapustyan are employees of AbbVie Inc. and may own stocks and/or options of the company. Sang Kyu Cho is a Health Economics and Outcomes Research fellow of AbbVie Inc. Scott Johnson, Suchin Virabhak and Hélène Parisé are employees of Medicus Economics, LLC. Medicus Economics, LLC received consulting fees for research from AbbVie. Arliene Ravelo and Sheila Shapouri are employees of Genentech, Inc. and may own stocks and/or options from Roche. Matthew Davids is an employee of the Dana Farber Cancer Institute. He has appointments for consultancy or is an advisory board member for Genentech, Gilead, Janssen, Astra-Zeneca, Verastem, MEI Pharma, AbbVie, TG Therapeutics, Pharmacyclics, Adaptive Biotechnologies, Sunesis, and Syros; and has institutional research funding from Pharmacyclics, TG Therapeutics, Genentech, Astra-Zeneca, Verastem, BMS, MEI Pharma, and Surface Oncology.